24mg of lenvatinib is orally taken once daily.

2 trials

Sponsors

National Cancer Center

Conditions

Thymic carcinomacolorectal cancer

Phase 2

A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy (NCCH1503,Lemon trial)

Active, not recruitingJPRN-UMIN000023446

National Cancer Centercolorectal cancer

Start: 2016-08-23Target: 30Updated: 2026-06-29

Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma;REMORA trial (NCCH1508,REMORA trial)

Active, not recruitingJPRN-UMIN000026777

National Cancer CenterThymic carcinoma

Start: 2017-04-13Target: 42Updated: 2026-06-29

Related Papers

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.

2024-03-3013 citations

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503).

2020-08-0116 citations

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.

2020-06-01162 citations

A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).

Journal of Clinical Oncology2019-05-203 citations